Navigation Links
Study identifies a likely key driver of colorectal cancer development and progression
Date:4/14/2014

COLUMBUS, Ohio A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

The study of microRNA-135b (miR-135b) in two animal models and human tumors was published in the journal Cancer Cell and was led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at the University of Glasgow in the United Kingdom.

The researchers demonstrate that miR-135b is present at abnormally high levels in both mouse and human colorectal (CRC) tumors. The overexpression can be induced by the mutations in either well-known oncogenes or tumor-suppressor genes that frequently occur in CRC, the researchers say.

"We found that miR-135b is up-regulated in both sporadic and inflammatory bowel disease-associated colorectal cancer, and that its up-regulation is associated with tumor stage and poor clinical outcome," says principal investigator Carlo M. Croce, MD, chair of molecular virology, immunology and medical genetics, and director of Human Cancer Genetics at Ohio State and the OSUCCC James.

"Our findings provide proof-of-principle that anti-miR-135b has significant therapeutic potential in colorectal cancer treatment," says Croce, who is also the John W. Wolfe Chair in Human Cancer Genetics.

For this study, Croce and his collaborators used a CRC mouse model based on loss of a tumor suppressor and a model based on inflammation and oncogene activation; human tumors from a cohort of sporadic CRC and inflammatory-bowel-disease associated CRC; human and animal cell lines and data from The Cancer Genome Atlas.

Key findings included:

  • MiR-135b up-regulation occurs in both sporadic and inflammatory bowel disease-associated CRC, and it is associated with tumor
    '/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study gives high marks to NC Pre-K program
2. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
3. Study links domestic abuse to mental health problems in new mothers
4. Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds
5. Lipid levels during prenatal brain development impact autism: York U study
6. ED dental care treatment raises access, cost issues for policymakers, Rutgers study finds
7. $2.5 million Defense Department grant funds gene therapy study for Lou Gehrigs disease
8. Study finds link between childs obesity and cognitive function
9. Study reveals animal research bias in experimentation oversight committee membership
10. Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders
11. Obesity primes the colon for cancer, according to NIH study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... October 20, 2014 Punzoné , the ... the U.S., has a lot to celebrate this month. October ... recognizes the achievements and contributions of Americans of Italian heritage ... Punzoné, and today it shares its favorite Italian cocktails and ... to Italy - even if it is only in a ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... the Drugs for Neglected Diseases initiative (DNDi) today ... for leishmaniasis, Chagas disease, and sleeping sickness, three ... 10 million people worldwide. Novel drug candidates to ... development pipeline for new medicines urgently needed by ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, ... drug significantly cuts the risk of painful pancreatitis ... the digestive tract, a new study suggests. ... administered rectally after the procedure -- known as ...
... The spouses of cancer patients are at increased risk of ... said the explanation might be that stress takes a toll ... cancer registry and the Swedish inpatient registry, researchers found that ... 29 percent in people whose partner had cancer. "Our ...
... is growing rapidly as California,s population ages, but the majority ... have poor access to health care and food, a new ... found. Fifty-seven percent of paid Medi-Cal caregivers ... the state have incomes that leave them in poverty ...
... undergoing treatment for breast cancer can experience cognitive declines, ... and attention. Often experienced by patients undergoing chemotherapy, the ... health psychologist at the University of Missouri says "chemo ... associate professor and chair of the Health Psychology Department ...
... Being nice may be in your genes. That,s according ... least part of the reason why some people are kind ... the University of California, Irvine assessed the behavior of people ... oxytocin and vasopressin -- believed to make people nicer. ...
Cached Medicine News:Health News:AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases 2Health News:Drug May Prevent Pancreatitis After Digestive Procedure 2Health News:Majority of California's Medi-Cal caregivers live in or near poverty 2Health News:Majority of California's Medi-Cal caregivers live in or near poverty 3Health News:Stress contributes to cognitive declines in women with breast cancer, researcher says 2Health News: Some Folks Just Can't Help Being Nice, Study Suggests 2
(Date:10/17/2014)... 17, 2014  Talyst, a market leader in pharmacy ... Meeting in Nashville, TN. The ... leading solution for onsite, remote medication dispensing. ... to safely and securely dispense medication onsite, on demand. ... helps ensure that the correct medication gets to the ...
(Date:10/17/2014)... CHICAGO , Oct. 17, 2014   InnFocus, Inc ... the United States for up to ... Ophthalmology Innovation Summit in Chicago . ... the beginning of the annual meeting of the American ... to have treated approximately 150 glaucoma patients in 6 countries ...
(Date:10/17/2014)... 17, 2014  China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... has received approval from the China Food and ... human prothrombin complex concentrate ("PCC") at its Shandong ... coagulation factor production facility for Good Manufacturing Practices ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Motor System Disorders, LA JOLLA, Calif., Oct. ... clinical development by TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... was shown,in an independent study to be effective ... a rat model of spinal ischemia. These symptoms,are ...
... PHRM ) today announced the initiation of ... the Company,s third-generation,synthetic anthracycline, in the treatment of ... multi-center study will compare,amrubicin to topotecan, the only ... US and EU. Enrollment in the study of ...
Cached Medicine Technology:Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 2Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 3Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego 4Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 2Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 3Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 4Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 5
AllMeds was the first specialty-specific Electronic Medical Record for Neurosurgery. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Neu...
... software It runs over hospital ... PAS systems and some items ... collects data at initial consultation, ... checks, operation, post-op checks, telephone ...
... Medical Office (EMO) for the Ophthalmology ... of your practice. In addition to ... an EMO electronically integrates the patient ... encounters, information about patients, and billing ...
... patient care reports for cardiology and ... reporting and documentation tool, physicians can ... H&P, labs, medications, and procedural details. ... with an e-signature, and distributed at ...
Medicine Products: